C-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death by Hertog, H.M. (Heleen) den et al.
ORIGINAL COMMUNICATION
C-reactive protein in the very early phase of acute ischemic
stroke: association with poor outcome and death
H. M. den Hertog Æ J. A. van Rossum Æ H. B. van der Worp Æ
H. M. A. van Gemert Æ R. de Jonge Æ P. J. Koudstaal Æ
D. W. J. Dippel Æ the PAIS investigators
Received: 19 January 2009 / Revised: 17 June 2009 / Accepted: 30 June 2009 / Published online: 17 July 2009
 The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract Acute ischemic stroke may trigger an inflam-
matory response that leads to increased levels of
C-reactive protein (CRP). High levels of CRP may be
associated with poor outcome because they reflect either
an inflammatory reaction or tissue damage. We evaluated
the prognostic value of CRP within 12 h of onset of
ischemic stroke. Levels of CRP were routinely obtained
within 12 h of symptom onset in 561 patients with
ischemic stroke. CRP values were dichotomized as \7 or
C7 mg/L. The full range of CRP values was used to
detect a possible level-risk relationship. We studied the
relation between CRP values and poor outcome (modified
Rankin Scale score [2) or death at 3 months. A multiple
logistic regression model was applied to adjust for age,
sex, NIHSS score, current cigarette smoking, diabetes
mellitus, hypertension, statin use, and stroke subtype.
After adjustment for potential confounders, patients with
CRP levels C7 mg/L had a significantly increased risk of
poor outcome (adjusted OR 1.6, 95% CI 1.1–2.4) or death
(adjusted OR 1.7, 95% CI 1.0–2.9) at 3 months. In
addition, the risk of poor outcome or death at 3 months
increased with higher levels of CRP. CRP within 12 h of
ischemic stroke is an independent prognostic factor of
poor outcome at 3 months.
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Background
Elevated serum levels of C-reactive protein (CRP) are
found in up to three quarters of patients with ischemic
stroke [8, 26]. Increases in CRP may reflect a systemic
inflammatory response following ischemic stroke, the
extent of tissue injury, or concurrent infections. Moreover,
in animal models of focal cerebral ischemia, CRP
increased secondary brain damage through activation of the
complement system [13, 22].
Several studies have assessed the value of CRP in the
very early phase of stroke as a prognostic factor of func-
tional outcome. These studies were either small, included a
selected group of patients, or tested only the relation
between CRP and mortality instead of functional outcome.
The findings were inconclusive as some found a positive
association [6, 18, 20], but others not [27, 30].
Verification of the role of CRP as an early prognostic
factor of functional outcome after ischemic stroke may be
of clinical importance, because it is an easily-measured and
readily available inflammatory marker. The aim of our
study was therefore to determine the prognostic value of
CRP measured in the very early phase of ischemic stroke
for poor functional outcome and death in a large sample of
patients with acute ischemic stroke.
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Methods
Study design
All patients included in the present study participated in the
Paracetamol (Acetaminophen) In Stroke (PAIS) trial, a
multicenter, randomized, placebo-controlled clinical trial of
high-dose paracetamol in patients with acute stroke. The
study protocol has been published earlier [7, 28]. In short,
patients with ischemic stroke or intracerebral hemorrhage
within 12 h of symptom onset with no history of liver disease
or pre-stroke impairment (modified Rankin Scale (mRS)
score \2) [29] were included in this study. Patients with
ischemic stroke included in the PAIS trial between March
2003 and March 2007 in centers where CRP was measured as
a part of routine laboratory assessment on admission were
included in the present study if venous blood sampling for
CRP was accomplished within 12 h of symptom onset.
Baseline variables
Baseline clinical information was extracted from the trial
records. This included body temperature on admission and
24 h later, stroke subtype according to the TOAST classi-
fication [1], stroke severity as assessed with the NIH Stroke
Scale (NIHSS) [5], and cardiovascular risk factors. In
addition, the occurrence of infections during hospitaliza-
tion was assessed. Body temperature was measured with
either tympanic or rectal thermometers.
Blood samples and CRP assay
Blood samples for assessment of CRP and white blood cell
count were taken on admission. The time of CRP mea-
surement relative to stroke onset was recorded in all
patients.
Levels of CRP were determined with a clinically vali-
dated assay. Participating centers used different analyzers
(Dade Behring, Beckman LX-20, Beckman Synchron,
Beckman Coulter DXC, Olympus 640, Ortho Vitros, Roche
Cobas 6000, Roche Cobas Integra, Roche Hitachi 917,
Roche Modular) to establish CRP levels. Intra- and inter-
assay variation of all participating centers was evaluated by
means of the external quality control scheme of the Dutch
Foundation for Quality Assessment in Clinical Laborato-
ries (SKML). If the intra-assay and/or inter-assay coeffi-
cient of variation was higher than 7.5%, patients from these
centers were excluded from further analysis. All centers
were subjected to quality review by the Dutch Foundation
for Quality Assessment in Clinical Laboratories (SKML
(http://www.skml.nl).
Some centers did not report exact values of CRP below a
certain cut-off point, as values below these cut-off points
were considered ‘‘normal’’ values. These cut-off points
varied between 1 and 7 mg/L.
As extremely high levels of CRP likely reflect an
infection at the time of blood sampling, patients in whom
the level of CRP was higher than 2 SD above the mean
were excluded from further analysis.
Outcome measures
Poor outcome was defined as a score of more than 2 on the
mRS, including death, at 3 months from stroke onset. A
secondary outcome was death at 3 months. Outcome was
assessed without knowledge of baseline CRP levels.
Statistical analysis
Statistical analyses were performed with Stata/SE 8.2 for
Windows (Statacorp, College Station, Texas, USA). The
relation between outcome and dichotomized CRP levels
was expressed as an odds ratio (OR), with a corresponding
95% confidence interval (CI), through logistic regression.
CRP values were dichotomized at 7 mg/L. This cut-off
point was selected, as this was the highest cut-off point
below which values were considered normal and not
reported as exact values by some centers. In order to study
a possible level-risk relationship, all CRP values were
recoded with 7 mg/L as the lower bound. Odds ratios were
expressed per unit increase in logarithmically transformed
CRP levels. Adjustments for the impacts of age, sex,
baseline NIHSS score, cigarette smoking status, diabetes
mellitus, hypertension, statin use, and stroke subtype
(cardioembolic stroke versus non-cardioembolic stroke)
was made with multiple logistic regression. We performed
additional analyses to account for the potential confound-
ing effect of antipyretic treatment by stratifying for treat-
ment with acetaminophen.
Results
Between 1 March 2003 and 1 March 2007, 1187 patients
were included in the PAIS trial. Sixteen of the 29 partici-
pating centers routinely performed CRP measurements on
admission for acute stroke. In these 16 centers, 897 patients
where included in the PAIS trial in the period under study.
Of these patients, 336 were excluded from the present
study because of hemorrhagic stroke (n = 117), CRP
measurement not accomplished within 12 h of stroke onset
or time of assessment unknown (n = 54), CRP measure-
ments with analyzers with a variation coefficient [7.5%
(n = 56), or CRP levels over 110 mg/L (2 SD; n = 9).
The median CRP level was 5 mg/L (IQR 2–8) and 33%
of patients had CRP levels of 7 mg/L or above.
2004 J Neurol (2009) 256:2003–2008
123
Table 1 shows the baseline characteristics of the patients
with CRP levels \7 or C7 mg/L. Median time from onset
of symptoms to CRP measurement was 137 min (range 0–
696). Patients with CRP C7 mg/L were older, had higher
scores on the NIHSS, had a slightly higher body temper-
ature on admission, were more often smokers, more fre-
quently had hypertension, diabetes mellitus, or atrial
fibrillation, and less often used statins than patients with
low CRP levels. Cardioembolic strokes were observed
more often in patients with CRP C7 mg/L.
Sixteen patients with CRP C7 mg/L (9%) and 15
patients (4%) with CRP \7 mg/L developed an infection
during hospitalization. Two patients with CRP C7 mg/L
had an infection (both pneumonia) within 24 h of stroke
onset. No infections within 24 h were reported in patients
with CRP \7 mg/L.
No association between CRP levels and the body tem-
perature at 24 h after study enrollment was found.
Patients with CRP levels C7 mg/L more often had a
poor outcome (57 versus 42%; p = 0.006) or died (23
versus 13%; p = 0.0007) than patients with lower CRP
levels (Fig. 1). Adjustment for potential confounders did
not change these results (Table 2).
An additional stratified analysis to account for the
potential confounding effect of treatment with acetamino-
phen did not affect the association.
A level-risk relationship was observed between CRP
and poor outcome or death at 3 months. The relation
Table 1 Baseline
characteristics of the study
population
a Scores on the National
Institutes of Health Stroke Scale
(NIHSS) range from 0 to 42,
with higher values indicating
more severe stroke [5]
b Based on the definitions of the
Trial of ORG 10172 in Acute
Stroke Therapy (TOAST)
criteria [1]
CRP \ 7 mg/L CRP C 7 mg/L p
Demographics
N 377 184 0.07
Age (years), mean (SD) 69.1 (13.4) 70.9 (13.8) 0.98
Male 226 (60%) 110 (60%)
Stroke severitya
NIHSS, mean (SD) 7.5 (6.0) 8.9 (6.6) 0.02
Risk factors
Arterial hypertension 183 (49%) 107 (58%) 0.03
Atrial fibrillation 47 (12%) 47 (26%) 0.0005
Diabetes mellitus 50 (13%) 37 (20%) 0.03
Current cigarette smoking 108 (29%) 70 (38%) 0.03
Hypercholesterolemia 104 (28%) 42 (23%) 0.30
History
Stroke 84 (22%) 40 (22%) 0.68
Myocardial infarction 47 (12%) 25 (14%) 0.92
Peripheral vascular disease 25 (7%) 21 (11%) 0.09
Physical examination
Systolic blood pressure, mean (SD) 169 (31) 171 (34) 0.63
Diastolic blood pressure, mean (SD) 89 (18) 89 (21) 0.81
Body temperature, mean (SD) 36.9 (0.6) 37.0 (0.6) 0.08
Laboratory assessments
Time until CRP measurement (min), median (range) 140 (2–696) 129 (0–681) 0.64
Leukocytes 109/L, mean (SD) 8.2 (2.6) 9.4 (3) 0.0001
Stroke type (TOAST)b
Undetermined 189 (50%) 81 (44%) 0.09
Large vessel disease (C50% stenosis) 38 (10%) 28 (15%) 0.06
Cardiac source of embolism 60 (16%) 44 (24%) 0.02
Small vessel occlusion 49 (13%) 24 (13%) 0.88
Other determined etiology 41 (11%) 7 (4%) 0.003
Treatment
RtPA 95 (25%) 50 (27%) 0.42
Ace inhibitor 65 (17%) 38 (21%) 0.46
Statin 101 (27%) 36 (20%) 0.001
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between CRP and poor outcome was attenuated after
adjustment for potential confounders (Table 3).
After exclusion of patients who developed an infection
during the first 2 weeks after stroke onset, the adjusted
odds ratio for poor outcome was 1.5 (95% CI 1.0–2.3;
p = 0.07), and for death 1.9 (95% CI 1.1–3.4).
Discussion
In this study, patients with CRP levels C7 mg/L within
12 h of ischemic stroke onset had a significantly increased
risk of poor functional outcome or death at 3 months, even
after adjustment for potential confounders. In addition, a
level-risk relationship was found between CRP and poor
outcome and death.
Several studies have found an association between
increased CRP levels and clinical outcome in the time
window between 12 and 72 h after ischemic stroke [6, 8, 9,
15, 18, 20, 21, 25–27, 30]. The results of previous studies
that have aimed to assess the prognostic value of CRP in
the very early phase of stroke are ambiguous. Two pro-
spective studies did not observe a relation between CRP
levels obtained within 6 or 12 h after symptom onset and
death or dependency at follow-up [27, 30]. Both studies
were rather small (127 and 111 patients) and may therefore
have lacked the power to detect an association. In addition,
one of these studies included only patients treated with rt-
PA [27].
In line with our results, three other studies found an
association between CRP and outcome. In one of these
studies, CRP was measured within 24 h of stroke onset,
and 25% of the patients had a transient ischemic attack
(TIA) instead of a stroke, which may have influenced the
observed association [6]. In addition, only the relation
between CRP and mortality, and not disability, was stud-
ied. Other studies included only patients aged 75 years or
older [18], or patients who had a middle cerebral artery
occlusion and received rt-PA [20]. In the latter, an asso-
ciation with mortality was found, but functional outcome
was not assessed [20].
The strengths of the present study are its large sample
size, robust outcome measures and early CRP measure-
ment, which increase the relevance of our findings. Fur-
thermore, detailed information on confounders was
available.
Some methodological limitations should be discussed.
First, this study was part of a larger clinical trial, and not
designed to evaluate the prognostic value of CRP with
regard to clinical outcome in acute ischemic stroke. As a
consequence, a detailed history of inflammatory conditions
was not recorded.
Levels were determined with different analyzers, which
may have resulted in a systematic error. For this reason,
measurements performed with analyzers with an inter-
assay coefficient of variation C7.5% or that demonstrated
bias relative to the other participating centers were exclu-
ded from further analysis. Secondly, the lowest detection
limit for CRP varied from 1 to 7 mg/L among the centers.
Therefore, CRP levels had to be dichotomized. This makes
it more difficult to compare our results with previous
studies. However, in three of the five studies that assessed
the relation between CRP levels in the very early phase of
acute stroke and clinical outcome, a similar cut-off point
level was selected [20, 27, 30]. Furthermore, all CRP
values were recoded with 7 as the lower bound, in order to
study a possible level-risk relationship.
Fig. 1 Association of CRP levels on admission with poor outcome or
death at 3 months
Table 2 Association between increased CRP (C7 mg/L) at baseline
and outcome after ischemic stroke
OR (95% CI) Adjusted OR (95% CI)a
Poor outcome (mRS [ 2) 1.9 (1.3–2.7) 1.6 (1.1–2.4)
Death 2.0 (1.3–3.2) 1.7 (1.0–2.9)
a Adjusted for age, sex, NIHSS score, cigarette smoking, diabetes
mellitus, hypertension, statin use, and stroke subtype
Table 3 Level-risk relationship CRP and outcome
ORa (95% CI) Adjusted ORa, b (95% CI)
Poor outcome (mRS [ 2) 1.6 (1.2–2.2) 1.3 (0.9–1.9)
Death 2.1 (1.5–3.0) 1.9 (1.2–2.8)
a ORs were expressed per 1 unit increase in logarithmically trans-
formed CRP levels
b Adjusted for age, sex, NIHSS score, cigarette smoking, diabetes
mellitus, hypertension, statin use, and stroke subtype
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A fourth issue might be that rather few patients with
very severe stroke were included, which may affect the
generalisability of the results.
In patients with ischemic stroke, increased levels of CRP
may reflect a pre-existing degree of atherosclerosis or the
presence of vascular risk factors. We found that patients
with higher levels of CRP were more often smokers and
more frequently had hypertension, diabetes mellitus, or
atrial fibrillation. Furthermore, cardioembolic strokes were
observed more often in patients with higher levels of CRP.
Moreover, patients with CRP C7 mg/L used statins less
often than patients with low CRP levels, suggesting that
drugs in this class reduce levels of CRP. These findings are
supported by previous studies [2, 10, 17, 18, 23, 24].
Why could CRP concentration be a prognostic factor for
poor outcome and death? Early after onset of ischemic
stroke, increased CRP levels may reflect an accompanying
inflammatory reaction. Inflammatory processes play an
important role in the pathophysiology of ischemic stroke
[19]. Cerebral ischemia triggers an inflammatory response
characterized by activation and release of acute phase pro-
teins such as C-reactive protein (CRP) and cytokines [4, 16,
19]. The inflammatory processes may start within 2 h after
stroke onset and sustain for days [25], and may contribute to
ischemic brain damage even in that early stage [11].
Elevated CRP levels may be a reflection of the extent of
brain injury. In our study, patients with CRP levels C7 mg/L
had higher NIHSS scores on admission. Previous studies
have shown that patients with increased CRP levels have
larger infarctions [25]. Although patients with CRP levels
C7 mg/L taken as a group had worse outcomes at 3 months
as assessed with the mRS, multiple logistic regression
modeling indicated that the adverse outcome in this group
remained even after adjustment for initial stroke severity by
NIHSS score and multiple other risk factors for poor out-
come. This suggests that CRP not only reflects the amount of
tissue damage, but may also indicate a state of enhanced risk
due to increased inflammation or cytokine excess. Interest-
ingly, recent experimental studies have shown that CRP
itself may contribute to secondary brain damage after focal
cerebral ischemia, possibly via a complement-mediated
exacerbation of tissue injury [13, 22]. In rats, treatment with
human CRP after middle cerebral artery occlusion resulted
in larger infarcts [13]. Similar results have been observed in
experimental models of myocardial infarction [14].
It is therefore conceivable that increased levels of CRP
following stroke are not only a consequence of brain
infarction, but contribute to ischemic damage as well.
Increased CRP levels following ischemic stroke may
also reflect concurrent infections. Secondary infections are
common in the first week of stroke and are associated with
poor outcome [3, 11, 12], but they usually occur more than
12 h after stroke onset. In our study, only two clinically
overt infections were reported within 24 h after stroke
onset. In addition, we excluded patients in whom the CRP
level exceeded 2 SD above the mean, who may have had
an infection before stroke onset. Furthermore, exclusion of
patients developing an early infection during hospitaliza-
tion did not substantially affect the relation between CRP
levels and poor functional outcome or death.
The use of biomarkers as predictors of stroke lesion
evolution and prognosis is becoming increasingly important,
as they may be valuable tools in the search for an optimal
management of stroke patients. The present study confirms
results from previous studies that have advocated CRP as a
powerful prognostic marker in patients with ischemic stroke
[6, 8, 9, 15, 18, 20, 21, 25, 30]. It may provide important
prognostic information beyond conventional clinical
parameters. Further studies are needed to assess whether
CRP is also a predictor of outcome after stroke.
Moreover, the fact that animal studies have found that
CRP might exacerbate brain tissue damage following
ischemic stroke, might stimulate research into the underly-
ing pathogenetic mechanisms and development of new,
more targeted, medical treatments for acute ischemic stroke.
Conclusion
Elevated CRP levels in the very early phase of acute
ischemic stroke are independent prognostic factors for poor
outcome at 3 months.
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